Loading clinical trials...

COMPLETED

Ragweed-SPIRE Follow-On Study

An Observational Follow-On Field Study to Evaluate the Continued Efficacy and Safety of Ragweed-SPIRE Treatment in Ragweed Allergic Subjects Approximately One Year After the Completion of Treatment

NCT02396680•Circassia Limited

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine the efficacy of Ragweed-SPIRE 12 months after the initial dose.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•° Previously randomised into and completed at least 6 of 8 treatment visits in Study TR006

Exclusion Criteria

•Subject or Investigator have been informed of treatment received in Study TR006
•Subjects with significant allergy to animal dander
•Any allergen immunotherapy since completing Study TR006 or use of prohibited therapies
•History of recurrent acute sinusitis or chronic sinusitis
•Received treatment with an investigational drug within 4 weeks of Screening
•Unable to understand study requirements or unable to communicate clearly with Investigator

Locations (3)

Kanata Allergy Services

Kanata, Ontario, Canada

Inflamax Research

Mississauga, Ontario, Canada

Windsor Allergy Asthma Associates

Windsor, Ontario, Canada

Key Dates

Start Date

April 1, 2015

Primary Completion Date

February 1, 2016

Last Updated

March 23, 2016

Enrollment

249

ACTUAL participants

Conditions

RhinoconjunctivitisRagweed Allergy

Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites

NCT04435990

Rhinitis, AllergicRhinoconjunctivitis+1 more

View study

RECRUITINGPHASE4

Evaluation of the Efficacy of Allergen-specific Immunotherapy Using Assessment in an Allergen Exposure chamber-a Randomized Placebo-controlled Double-blind Study

NCT06778213

Allergic Rhinoconjunctivitis

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 23, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Ragweed-SPIRE Follow-On Study

Inclusion Criteria

Exclusion Criteria

Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites

Evaluation of the Efficacy of Allergen-specific Immunotherapy Using Assessment in an Allergen Exposure chamber-a Randomized Placebo-controlled Double-blind Study

Retrospective Study Evaluating the Effectiveness and Safety of Immunotherapy With Clustoid Max Forte

Study of BLU-808 in Allergic Rhinoconjunctivitis

Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction

A Motivation-enhancing App to Retain Patients With Hay Fever in a Trial After Treatment